To evaluate efficacy of an immunomodulator thymosin alpha 1 in women with previous IVF failure at rural setup

to evaluate efficacy of an immunomodulator thymosin alpha 1 in women with previous IVF failure A Randomised controlled trial - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/08/092706

Enrollment

Registered

2025-08-08

Start date

Unknown

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N00-N99- Diseases of the genitourinary system

Interventions

Intervention1: Immunomodulator in patients with previous IVF failure: thymosin alpha 1 injection 1.6 mg two injections alternate day subcutaneously in embryo transfer preparation phase of 21 days upti

Eligibility

Inclusion criteria

Inclusion criteria: patients of IVF with previous 1 IVF failure with informed consent

Exclusion criteria

Exclusion criteria: known systemic autoimmune condition or known chromosomal abnormalities

Design outcomes

Primary

Measure	Time frame
to evaluate efficacy of thymosin alpha 1 as an add on tretment to basic hormone therapy in frozen embryo transfer patientsTimepoint: positive pregnancy outcome with urine pregnancy test at 4 weeks and ultrasonography at 6 weeks for fetal cardiac activity will be evaluated	—

Secondary

Measure	Time frame
to evaluate changes in clinical pregnancy rates following thymosin alpha 1 administrationTimepoint: to check urine pregnacy positivity & ultrasonography at 6 weeks for clinical pregnancy positive rate with thymosin alpha 1 injections	—

Countries

India

Contacts

Public ContactDr Deepika Dhundi

Datta Meghe institute of higher education and research

dr.kamleshchaudhari@gmail.com9320568673

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026